EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sinopharm Group Co's enterprise value is $9,700 Mil.
Sinopharm Group Co's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $1,659 Mil. Therefore, Sinopharm Group Co's EV-to-EBITDA for today is 5.85.
The historical rank and industry rank for Sinopharm Group Co's EV-to-EBITDA or its related term are showing as below:
SHTDF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.12 Med: 9.18 Max: 13.88
Current: 5.85
During the past 13 years, the highest EV-to-EBITDA of Sinopharm Group Co was 13.88. The lowest was 3.12. And the median was 9.18.
SHTDF's EV-to-EBITDA is ranked better than 70.37% of 81
companies
in the Medical Distribution industry
Industry Median: 9.91
vs SHTDF: 5.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-25), Sinopharm Group Co's stock price is $2.61.
Sinopharm Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.394. Therefore, Sinopharm Group Co's PE Ratio for today is 6.62.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Sinopharm Group Co EV-to-EBITDA Historical Data
The historical data trend for Sinopharm Group Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sinopharm Group Co's EV-to-EBITDA
For the Medical Distribution subindustry, Sinopharm Group Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co's EV-to-EBITDA Distribution in the Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's EV-to-EBITDA falls into.
Sinopharm Group Co EV-to-EBITDA Calculation
Sinopharm Group Co's EV-to-EBITDA for today is calculated as:
Sinopharm Group Co's current Enterprise Value is $9,700 Mil.
Sinopharm Group Co's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,659 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co (OTCPK:SHTDF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sinopharm Group Co's PE Ratio for today is calculated as:
Sinopharm Group Co's share price for today is $2.61.
Sinopharm Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.394.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Sinopharm Group Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Sinopharm Group Co (Sinopharm Group Co) Business Description
Sinopharm Group was founded in 2003 and listed on the Hong Kong Stock Exchange in September 2009. Its main business is drug distribution in mainland China, which contributes about 75% of total revenue. It is the largest drug distributor, with approximately 20% market share. Other notable segments are medical device distribution, which contributes about 20% of revenue, and retail pharmacies, which contributes about 5%. These are fast-growing industries, where government policy is designed to encourage consolidation and promote large players with scale and efficiency advantages.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHTDF has been successfully added to your 